Messenger RNA, or mRNA, has been a focus of research for scientists and drug developers for many years. It jumped to the forefront of the public consciousness when rapidly and successfully deployed as the platform for COVID-19 vaccines. The technology, however, promises to address a wider range of conditions, from cancers to cardiovascular disease to a broad array of infectious diseases. Learn more about the inner workings of mRNA and its promise as a treatment modality. 

Moderator

Matt Herper

Senior Writer, Medicine, Editorial Director of Events, STAT

Speakers

Vinod Balachandran

Member Researcher and Surgical Oncologist, David M. Rubenstein Center for Pancreatic Cancer Research

Thomas Conlon

Chief Scientific Officer, Michelson Philanthropies and the Michelson Found Animals Foundation

Mark Feinberg

President and CEO, International AIDS Vaccine Initiative (IAVI)

Ansbert Gadicke

Managing Partner, BioImpact Capital and Managing Director, MPM Capital

Mary Marovich

Director, Vaccine Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health